JP2023507799A5 - - Google Patents

Info

Publication number
JP2023507799A5
JP2023507799A5 JP2022538229A JP2022538229A JP2023507799A5 JP 2023507799 A5 JP2023507799 A5 JP 2023507799A5 JP 2022538229 A JP2022538229 A JP 2022538229A JP 2022538229 A JP2022538229 A JP 2022538229A JP 2023507799 A5 JP2023507799 A5 JP 2023507799A5
Authority
JP
Japan
Prior art keywords
cancer
product according
pharmaceutical product
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507799A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/065411 external-priority patent/WO2021127046A1/en
Publication of JP2023507799A publication Critical patent/JP2023507799A/ja
Publication of JP2023507799A5 publication Critical patent/JP2023507799A5/ja
Pending legal-status Critical Current

Links

JP2022538229A 2019-12-20 2020-12-16 組み合わせ Pending JP2023507799A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962952042P 2019-12-20 2019-12-20
US62/952,042 2019-12-20
US202063009754P 2020-04-14 2020-04-14
US63/009,754 2020-04-14
PCT/US2020/065411 WO2021127046A1 (en) 2019-12-20 2020-12-16 Combinations

Publications (2)

Publication Number Publication Date
JP2023507799A JP2023507799A (ja) 2023-02-27
JP2023507799A5 true JP2023507799A5 (cg-RX-API-DMAC7.html) 2023-12-25

Family

ID=76478099

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538229A Pending JP2023507799A (ja) 2019-12-20 2020-12-16 組み合わせ

Country Status (12)

Country Link
US (1) US20230042653A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069224A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023507799A (cg-RX-API-DMAC7.html)
KR (1) KR20220119428A (cg-RX-API-DMAC7.html)
CN (1) CN115103673A (cg-RX-API-DMAC7.html)
AU (1) AU2020408698A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012286A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165477A1 (cg-RX-API-DMAC7.html)
IL (1) IL294084A (cg-RX-API-DMAC7.html)
MX (1) MX2022007624A (cg-RX-API-DMAC7.html)
TW (1) TW202135810A (cg-RX-API-DMAC7.html)
WO (1) WO2021127046A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025085738A1 (en) 2023-10-18 2025-04-24 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2025189056A1 (en) 2024-03-08 2025-09-12 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5411847B2 (ja) * 2007-04-25 2014-02-12 Msd株式会社 Weelキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
CA2706946A1 (en) * 2007-11-28 2009-06-04 Schering Corporation 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
HRP20140821T1 (hr) * 2009-09-15 2014-10-10 Merck Sharp & Dohme Corp. Priprema kristalnih hemihidratnih oblika dihidropirazolopirimidinona
SMT201700595T1 (it) * 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
AU2016344040B2 (en) * 2015-11-01 2020-12-10 The Regents Of The University Of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
KR20220071293A (ko) * 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
US11932650B2 (en) * 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
EP3712150B1 (en) * 2017-11-01 2024-06-12 Wuxi Biocity Biopharmaceutics Co., Ltd. Macrocyclic compound serving as wee1 inhibitor and applications thereof
JP2022543832A (ja) * 2019-08-06 2022-10-14 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 変異体を治療するためのエストロゲン受容体調節剤

Similar Documents

Publication Publication Date Title
JP2023508325A5 (cg-RX-API-DMAC7.html)
Šarenac et al. Cervical cancer, different treatments and importance of bile acids as therapeutic agents in this disease
JP2023507797A5 (cg-RX-API-DMAC7.html)
Richie et al. Breast cancer: a review of the literature
Verschraegen et al. Clinicopathologic analysis of mullerian adenosarcoma: the MD Anderson Cancer Center experience.
JP5363310B2 (ja) 乳癌及び関連疾患に対する薬剤
Beckmann et al. Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates
Pontrelli et al. Primary vaginal adenosarcoma with sarcomatous overgrowth arising in recurrent endometriosis: feasibility of laparoscopic treatment and review of the literature
Malik et al. Medroxyprogesterone acetate (MPA) in advanced granulosa cell tumours of the ovary--a new therapeutic approach?
Yousefnia Breast cancer, subtypes, risk factors, and treatment
CN100408036C (zh) 阿那曲唑在制备用于治疗患有早期乳腺癌的绝经后的妇女的药物方面的用途
Soh et al. Clinical effects of danazol on endometrial hyperplasia in menopausal and postmenopausal women
Fan et al. Targeting Toll-like receptor 4 with CLI-095 (TAK-242) enhances the antimetastatic effect of the estrogen receptor antagonist fulvestrant on non-small cell lung cancer
Goodman Primary vaginal cancer
Erkanli et al. Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy
Ahmad et al. Frequency of primary solid malignant neoplasms in both sexes, as seen in our practice
Yu 17β‐Estradiol epoxidation as the molecular basis for breast cancer initiation and prevention
Lentini et al. Computed tomography in retroconversion of hepatic metastases from immature ovarian teratoma
Cetin et al. Squamous cell carcinoma of the vagina
Rodrigues-Fernandes et al. Oral epithelioid rhabdomyosarcoma: report of a rare case and literature review of a distinct variant of rhabdomyosarcoma
Benjamin et al. First report of primary fallopian tube cancer diagnosed by liquid-based cytology in an asymptomatic woman.
van der Veldt et al. Metastatic renal cell cancer in a 20-year-old pregnant woman
Zin et al. Primary Vaginal Melanoma–Cytohistological Correlates and Literature Reviews
Chakalova et al. Endometrial carcinoma in a 20 years old or less female: a rare presentation of four cases
Arslan et al. Case Report Isolated Uterine Metastasis of Invasive Ductal Carcinoma